Sign In
Buy AMRX
$18.09
+0.170 (+0.95%)
At Close: Jul 27, 2026
Amneal to Report First Quarter 2026 Results on May 1, 2026
04:01pm, Tuesday, 07'th Apr 2026
BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its first quarter 2
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness Month
08:00am, Tuesday, 07'th Apr 2026
BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced donations totaling $2 million to multiple patient
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $14.20 Average Target Price from Analysts
01:25am, Tuesday, 07'th Apr 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) has earned a consensus recommendation of "Buy" from the seven brokerages that are covering the company, MarketBeat.com reports. One resear
Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by SG Americas Securities LLC
05:25am, Monday, 30'th Mar 2026
SG Americas Securities LLC boosted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) by 2,866.0% in the undefined quarter, according to the company in its most recent disclosure wi
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
12:11pm, Friday, 20'th Mar 2026
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a po
Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy
03:09pm, Monday, 16'th Mar 2026
Amneal Pharmaceuticals, Inc. remains a Buy, with 45-55% upside potential and a $5-6bn market cap target in my opinion. AMRX delivered strong 2025 results—revenue up to $3.02bn, operating income $421
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
05:40pm, Tuesday, 10'th Mar 2026
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
New Strong Buy Stocks for March 9th
09:26am, Monday, 09'th Mar 2026
ECG, AMRX, NESR, ACMR and HSY have been added to the Zacks Rank #1 (Strong Buy) List on March 9th, 2026.
Best Value Stocks to Buy for March 9th
08:16am, Monday, 09'th Mar 2026
AMRX, VET and NESR made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 9th, 2026.
Amneal to Participate in Upcoming Investor Conference
04:05pm, Thursday, 05'th Mar 2026
BRIDGEWATER, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, will participate in a fireside ch
Amneal Pharmaceuticals Q4 Earnings Call Highlights
05:05am, Monday, 02'nd Mar 2026
Amneal Pharmaceuticals (NASDAQ: AMRX) reported fourth-quarter and full-year 2025 results and outlined its 2026 outlook, highlighting growth across the business, expanding complex product launches, and
Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say
10:30am, Friday, 27'th Feb 2026
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript
10:17am, Friday, 27'th Feb 2026
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript
Amneal Pharmaceuticals (AMRX) Q4 Earnings Top Estimates
08:15am, Friday, 27'th Feb 2026
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.12 per share a year ago.
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
06:00am, Friday, 27'th Feb 2026
‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million ; GAAP Net Income of $35 million ; Diluted Inco
